In our own Xiangya cohort, the SLC26A4 expression in PCa samples was lower than that in benign prostatic hyperplasia tissues at both mRNA and protein levels, which was inconsistent with the results of the TCGA-PRAD cohort. Here, SLC26A4 is linked to prostate adenocarcinoma.